30 mar | 2024 Biomarkers of NRF2 signalling: Current status and future challenges. Morgenstern, C, Lastres-Becker, I , Demirdöğen, BC, Costa, VM, Daiber, A, Foresti, R, Motterlini, R, Kalyoncu, S, Arioz, BI, Genc, S, Jakubowska, M, Trougakos, IP, Piechota-Polanczyk, A, Mickael, M, Santos, M, Kensler, TW, Cuadrado, A , Copple, IM. Redox Biol - 72 : 103134 (PMID: 38643749) (doi:10.1016/j.redox.2024.103134)
4 ago | 2023 Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration? Brackhan, M , Arribas-Blazquez, M , Lastres-Becker, I . Antioxidants (Basel) - 12 (8) (PMID: 37627559) (doi:10.3390/antiox12081564)
10 mayo | 2023 Special Issue "Role of NRF2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches II". Lastres-Becker, I . Biomolecules - 13 (5) (PMID: 37238683) (doi:10.3390/biom13050813)
4 mar | 2023 The Transcription Factor NRF2 Has Epigenetic Regulatory Functions Modulating HDACs, DNMTs, and miRNA Biogenesis. Silva-Llanes, I , Shin, CH, Jiménez-Villegas, J , Gorospe, M, Lastres-Becker, I . Antioxidants (Basel) - 12 (3) (PMID: 36978889) (doi:10.3390/antiox12030641)
29 ago | 2022 New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Lastres-Becker, I , de Lago, E, Martínez, A, Fernández-Ruiz, J. Biomolecules - 12 (9) (PMID: 36139039) (doi:10.3390/biom12091200)
5 ene | 2022 Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis. Martín-Cámara, O, Arribas, M , Wells, G, Morales-Tenorio, M, Martín-Requero, Á, Porras, G, Martínez, A, Giorgi, G, López-Alvarado, P, Lastres-Becker, I , Menéndez, JC. J Med Chem (PMID: 34985276) (doi:10.1021/acs.jmedchem.1c01255)
1 nov | 2021 Editorial: Tau Protein: Mechanisms From Health to Degeneration. Lastres-Becker, I . Front Mol Neurosci - 14 : 743986 (PMID: 34790096) (doi:10.3389/fnmol.2021.743986)
5 oct | 2021 α-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks. García-Yagüe, ÁJ , Lastres-Becker, I , Stefanis, L, Vassilatis, DK, Cuadrado, A . Mol Neurobiol (PMID: 34609698) (doi:10.1007/s12035-021-02558-9)
17 mayo | 2021 Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Galán-Ganga, M , Rodríguez-Cueto, C, Merchán-Rubira, J, Hernández, F, Ávila, J, Posada-Ayala, M, Lanciego, JL, Luengo, E, Lopez, MG, Rábano, A, Fernández-Ruiz, J, Lastres-Becker, I . Acta Neuropathol Commun - 9 (1) : 90 (PMID: 34001284) (doi:10.1186/s40478-021-01196-5)
16 mar | 2021 Molecular Alterations in Sporadic and SOD1-ALS Immortalized Lymphocytes: Towards a Personalized Therapy. Lastres-Becker, I , Porras, G, Arribas-Blázquez, M , Maestro, I, Borrego-Hernández, D, Boya, P, Cerdán, S , García-Redondo, A, Martínez, A, Martin-Requero, Á. Int J Mol Sci - 22 (6) (PMID: 33809456) (doi:10.3390/ijms22063007)
8 feb | 2021 Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Klionsky, DJ, [ .., ], Bartolome, A , [ .., ], Cuadrado, A , [ .., ], Escalante, R , [ .., ], García-Sanz, P , [ .., ], Lastres-Becker, I , [ .., ], León, Y , [ .., ], Martin-Sanz, P , [ .., ], Pajares, M , [ .., ], Rojo, AI , [ .., ], Valverde, AM , [ .., ], Varela-Nieto, I , [ .., ], Villalobo, A , [ .., ], Vincent, O , [ .., ], Tong, CK. Autophagy (PMID: 33634751) (doi:10.1080/15548627.2020.1797280)
2 feb | 2021 Special Issue "Role of NRF2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches". Lastres-Becker, I . Biomolecules - 11 (2) (PMID: 33540503) (doi:10.3390/biom11020202)
8 sep | 2020 Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. Castro-Sánchez, S , Zaldivar-Diez, J, Luengo, E, López, MG, Gil, C, Martínez, A, Lastres-Becker, I . Neurobiol Aging - 96 : 148-154 (PMID: 33007689) (doi:10.1016/j.neurobiolaging.2020.09.006)
2 jun | 2020 NRF2 and Primary Cilia: An Emerging Partnership. Martin-Hurtado, A , Lastres-Becker, I , Cuadrado, A , Garcia-Gonzalo, FR . Antioxidants (Basel) - 9 (6) (PMID: 32498260) (doi:10.3390/antiox9060475)
25 sep | 2019 NRF2-dependent gene expression promotes ciliogenesis and Hedgehog signaling. Martin-Hurtado, A , Martin-Morales, R , Robledinos-Antón, N , Blanco, R , Palacios-Blanco, I , Lastres-Becker, I , Cuadrado, A , Garcia-Gonzalo, FR . Sci Rep - 9 (1) : 13896 (PMID: 31554934) (doi:10.1038/s41598-019-50356-0)
5 ago | 2019 Cannabinoid CB2 Receptor Modulation by the Transcription Factor NRF2 is Specific in Microglial Cells. Galán-Ganga, M , Del Río, R , Jiménez-Moreno, N, Díaz-Guerra, M , Lastres-Becker, I . Cell. Mol. Neurobiol. (PMID: 31385133) (doi:10.1007/s10571-019-00719-y)
1 abr | 2019 Role of MSK1 in the Induction of NF-κB by the Chemokine CX3CL1 in Microglial Cells. Galán-Ganga, M , García-Yagüe, ÁJ , Lastres-Becker, I . Cell. Mol. Neurobiol. - 39 (3) : 331-340 (PMID: 30830503) (doi:10.1007/s10571-019-00664-w)
6 feb | 2019 CX3CR1-deficient microglia shows impaired signalling of the transcription factor NRF2: Implications in tauopathies. Castro-Sánchez, S , García-Yagüe, ÁJ , Kügler, S, Lastres-Becker, I . Redox Biol - 22 : 101118 (PMID: 30769286) (doi:10.1016/j.redox.2019.101118)
1 ago | 2018 Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Castro-Sánchez, S , García-Yagüe, ÁJ , López-Royo, T , Casarejos, M, Lanciego, JL, Lastres-Becker, I . Glia - 66 (8) : 1752-1762 (PMID: 29624735) (doi:10.1002/glia.23338)
6 nov | 2017 Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Cuadrado, A , Kügler, S, Lastres-Becker, I . Redox Biol - 14 : 522-534 (PMID: 29121589) (doi:10.1016/j.redox.2017.10.010)
1 sep | 2016 Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation. Lastres-Becker, I , Nonis, D, Eich, F, Klinkenberg, M, Gorospe, M, Kötter, P, Klein, FA, Kedersha, N, Auburger, G. Biochim. Biophys. Acta - 1862 (9) : 1558-1569 (PMID: 27240544) (doi:10.1016/j.bbadis.2016.05.017)
10 jul | 2016 Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease. Lastres-Becker, I , García-Yagüe, AJ , Scannevin, RH, Casarejos, MJ, Kügler, S, Rábano, A, Cuadrado, A . Antioxid. Redox Signal. - 25 (2) : 61-77 (PMID: 27009601) (doi:10.1089/ars.2015.6549)
1 jul | 2015 Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate. Fittschen, M, Lastres-Becker, I , Halbach, MV, Damrath, E, Gispert, S, Azizov, M, Walter, M, Müller, S, Auburger, G. Neurogenetics - 16 (3) : 181-192 (PMID: 25721894) (doi:10.1007/s10048-015-0441-5)
1 jul | 2015 Nrf2 protects the lung against inflammation induced by titanium dioxide nanoparticles: A positive regulator role of Nrf2 on cytokine release. Delgado-Buenrostro, NL, Medina-Reyes, EI, Lastres-Becker, I , Freyre-Fonseca, V, Ji, Z, Hernández-Pando, R, Marquina, B, Pedraza-Chaverri, J, Espada, S , Cuadrado, A , Chirino, YI. Environ. Toxicol. - 30 (7) : 782-792 (PMID: 24615891) (doi:10.1002/tox.21957)
30 mayo | 2014 Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation. Cuadrado, A , Martín-Moldes, Z, Ye, J, Lastres-Becker, I . J. Biol. Chem. - 289 (22) : 15244-15258 (PMID: 24759106) (doi:10.1074/jbc.M113.540633)
15 ene | 2014 Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Lastres-Becker, I , Innamorato, NG , Jaworski, T, Rábano, A, Kügler, S, Van Leuven, F, Cuadrado, A . Brain - 137 (Pt 1) : 78-91 (PMID: 24277722) (doi:10.1093/brain/awt323)
1 oct | 2013 Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Martín-de-Saavedra, MD, Budni, J, Cunha, MP, Gómez-Rangel, V, Lorrio, S, Del Barrio, L, Lastres-Becker, I , Parada, E, Tordera, RM, Rodrigues, AL, Cuadrado, A , López, MG. Psychoneuroendocrinology - 38 (10) : 2010-2022 (PMID: 23623252) (doi:10.1016/j.psyneuen.2013.03.020)
1 sep | 2013 Ataxin-2 modulates the levels of Grb2 and SRC but not ras signaling. Drost, J, Nonis, D, Eich, F, Leske, O, Damrath, E, Brunt, ER, Lastres-Becker, I , Heumann, R, Nowock, J, Auburger, G. J. Mol. Neurosci. - 51 (1) : 68-81 (PMID: 23335000) (doi:10.1007/s12031-012-9949-4)
22 feb | 2013 Nuclear import and export signals control the subcellular localization of Nurr1 protein in response to oxidative stress. García-Yagüe, ÁJ , Rada, P , Rojo, AI , Lastres-Becker, I , Cuadrado, A . J. Biol. Chem. - 288 (8) : 5506-5517 (PMID: 23283970) (doi:10.1074/jbc.M112.439190)
15 jul | 2012 α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Lastres-Becker, I , Ulusoy, A, Innamorato, NG , Sahin, G, Rábano, A, Kirik, D, Cuadrado, A . Hum. Mol. Genet. - 21 (14) : 3173-3192 (PMID: 22513881) (doi:10.1093/hmg/dds143)
1 dic | 2011 Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Granado, N, Lastres-Becker, I , Ares-Santos, S, Oliva, I, Martin, E, Cuadrado, A , Moratalla, R. Glia - 59 (12) : 1850-1863 (PMID: 21882243) (doi:10.1002/glia.21229)
7 jul | 2010 A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. Kurz, A, Double, KL, Lastres-Becker, I , Tozzi, A, Tantucci, M, Bockhart, V, Bonin, M, García-Arencibia, M, Nuber, S, Schlaudraff, F, Liss, B, Fernández-Ruiz, J, Gerlach, M, Wüllner, U, Lüddens, H, Calabresi, P, Auburger, G, Gispert, S. PLoS ONE - 5 (7) : e11464 (PMID: 20628651) (doi:10.1371/journal.pone.0011464)
15 mayo | 2010 Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis. Niso-Santano, M, González-Polo, RA, Bravo-San Pedro, JM, Gómez-Sánchez, R, Lastres-Becker, I , Ortiz-Ortiz, MA, Soler, G, Morán, JM, Cuadrado, A , Fuentes, JM, , . Free Radic. Biol. Med. - 48 (10) : 1370-1381 (PMID: 20202476) (doi:10.1016/j.freeradbiomed.2010.02.024)
15 ago | 2009 Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Sagredo, O, González, S , Aroyo, I, Pazos, MR, Benito, C , Lastres-Becker, I , Romero, JP, Tolón, RM, Mechoulam, R, Brouillet, E, Romero, J, Fernández-Ruiz, J. Glia - 57 (11) : 1154-1167 (PMID: 19115380) (doi:10.1002/glia.20838)
1 jun | 2009 Role of microglial redox balance in modulation of neuroinflammation. Innamorato, NG , Lastres-Becker, I , Cuadrado, A . Curr. Opin. Neurol. - 22 (3) : 308-314 (PMID: 19359988) (doi:10.1097/WCO.0b013e32832a3225)
1 nov | 2008 Pituitary adenylate cyclase-activating polypeptide stimulates glial fibrillary acidic protein gene expression in cortical precursor cells by activating Ras and Rap1. Lastres-Becker, I , Fernández-Pérez, A , Cebolla, B , Vallejo, M . Mol. Cell. Neurosci. - 39 (3) : 291-301 (PMID: 18707003) (doi:10.1016/j.mcn.2008.07.009)
17 sep | 2008 Spinocerebellar ataxia 2 (SCA2). Lastres-Becker, I , Rüb, U, Auburger, G. Cerebellum - 7 (2) : 115-124 (PMID: 18418684) (doi:10.1007/s12311-008-0019-y)
15 mayo | 2008 Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Lastres-Becker, I , Brodesser, S, Lütjohann, D, Azizov, M, Buchmann, J, Hintermann, E, Sandhoff, K, Schürmann, A, Nowock, J, Auburger, G. Hum. Mol. Genet. - 17 (10) : 1465-1481 (PMID: 18250099) (doi:10.1093/hmg/ddn035)
15 dic | 2006 An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Lastres-Becker, I , Fernández-Ruiz, J. Curr. Med. Chem. - 13 (30) : 3705-3718 (PMID: 17168732)
1 abr | 2006 Endotoxin preconditioning protects neurones from in vitro ischemia: role of endogenous IL-1beta and TNF-alpha. Lastres-Becker, I , Cartmell, T, Molina-Holgado, F. J. Neuroimmunol. - 173 (1-2) : 108-116 (PMID: 16439029) (doi:10.1016/j.jneuroim.2005.12.006)
12 jul | 2005 Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Lastres-Becker, I , Molina-Holgado, F, Ramos, JA, Mechoulam, R, Fernández-Ruiz, J. Neurobiol. Dis. - 19 (1-2) : 96-9107 (PMID: 15837565) (doi:10.1016/j.nbd.2004.11.009)
7 jun | 2005 Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. González, S , Mena, MA, Lastres-Becker, I , Serrano, A, de Yébenes, JG, Ramos, JA, Fernández-Ruiz, J. Brain Res. - 1046 (1-2) : 195-206 (PMID: 15882845) (doi:10.1016/j.brainres.2005.04.010)
25 oct | 2004 Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Lastres-Becker, I , Bizat, N, Boyer, F, Hantraye, P, Fernández-Ruiz, J, Brouillet, E. Neuroreport - 15 (15) : 2375-2379 (PMID: 15640759)
8 mayo | 2004 Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. de Lago, E, de Miguel, R, Lastres-Becker, I , Ramos, JA, Fernández-Ruiz, J. Brain Res. - 1007 (1-2) : 152-159 (PMID: 15064146) (doi:10.1016/j.brainres.2004.02.016)
7 oct | 2003 The endocannabinoid system and Huntington's disease. Lastres-Becker, I , De Miguel, R, Fernández-Ruiz, JJ. Curr Drug Targets CNS Neurol Disord - 2 (5) : 335-347 (PMID: 14529364)
6 mayo | 2003 Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Lastres-Becker, I , Bizat, N, Boyer, F, Hantraye, P, Brouillet, E, Fernández-Ruiz, J. Neuroreport - 14 (6) : 813-816 (PMID: 12858038) (doi:10.1097/01.wnr.0000067781.69995.1b)
23 abr | 2003 Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Lastres-Becker, I , Gómez, M, De Miguel, R, Ramos, JA, Fernández-Ruiz, J. Neurotox Res - 4 (7-8) : 601-608 (PMID: 12709298) (doi:10.1080/10298420290030514)
19 mar | 2003 Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Lastres-Becker, I , de Miguel, R, De Petrocellis, L, Makriyannis, A, Di Marzo, V, Fernández-Ruiz, J. J. Neurochem. - 84 (5) : 1097-1109 (PMID: 12603833)
6 dic | 2002 Endocannabinoids and basal ganglia functionality. Fernández-Ruiz, J, Lastres-Becker, I , Cabranes, A, González, S, Ramos, JA. Prostaglandins Leukot. Essent. Fatty Acids - 66 (2-3) : 257-267 (PMID: 12052041) (doi:10.1054/plef.2001.0350)
16 ago | 2002 The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. Romero, J, Lastres-Becker, I , de Miguel, R, Berrendero, F, Ramos, JA, Fernández-Ruiz, J. Pharmacol. Ther. - 95 (2) : 137-152 (PMID: 12182961)
1 abr | 2002 Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Lastres-Becker, I , Hansen, HH, Berrendero, F, De Miguel, R, Pérez-Rosado, A, Manzanares, J, Ramos, JA, Fernández-Ruiz, J. Synapse - 44 (1) : 23-35 (PMID: 11842443) (doi:10.1002/syn.10054)
8 mar | 2002 Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Lastres-Becker, I , Berrendero, F, Lucas, JJ, Martín-Aparicio, E, Yamamoto, A, Ramos, JA, Fernández-Ruiz, JJ. Brain Res. - 929 (2) : 236-242 (PMID: 11864629)
20 dic | 2001 Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. López-Rodríguez, ML, Viso, A, Ortega-Gutiérrez, S, Lastres-Becker, I , González, S, Fernández-Ruiz, J, Ramos, JA. J. Med. Chem. - 44 (26) : 4505-4508 (PMID: 11741470)
1 dic | 2001 Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Lastres-Becker, I , Cebeira, M, de Ceballos, ML, Zeng, BY, Jenner, P, Ramos, JA, Fernández-Ruiz, JJ. Eur. J. Neurosci. - 14 (11) : 1827-1832 (PMID: 11860478)
1 sep | 2001 Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. Hansen, HH, Schmid, PC, Bittigau, P, Lastres-Becker, I , Berrendero, F, Manzanares, J, Ikonomidou, C, Schmid, HH, Fernández-Ruiz, JJ, Hansen, HS. J. Neurochem. - 78 (6) : 1415-1427 (PMID: 11579150)
20 jul | 2001 Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Lastres-Becker, I , Fezza, F, Cebeira, M, Bisogno, T, Ramos, JA, Milone, A, Fernández-Ruiz, J, Di Marzo, V. Neuroreport - 12 (10) : 2125-2129 (PMID: 11447320)
25 mayo | 2001 Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Di Marzo, V, Lastres-Becker, I , Bisogno, T, De Petrocellis, L, Milone, A, Davis, JB, Fernandez-Ruiz, JJ. Eur. J. Pharmacol. - 420 (2-3) : 123-131 (PMID: 11408034)
27 ago | 1999 Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. González, S, Romero, J, de Miguel, R, Lastres-Becker, I , Villanua, MA, Makriyannis, A, Ramos, JA, Fernández-Ruiz, JJ. Life Sci. - 65 (3) : 327-336 (PMID: 10447218)
1 nov | 1997 2'(3')-O-[N- [2- [3- [5-fluoresceinyl] thioureido] ethyl] carbamoyl] adenosine 5'-triphosphate and its Cr(H2O)4 and Co(NH3)4 complex derivatives are new fluorescent tools for labelling ATP binding sites of Na+/K+-ATPase. Linnertz, H, Lastres Becker, I , Krumscheid, R, Amler, E, Thoenges, D, Schoner, W. Physiol Res - 46 (5) : 345-349 (PMID: 9728479)